Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

4.03GBp
31 Oct 2014
Price Change (% chg)

0.00p (+0.00%)
Prev Close
4.03p
Open
4.03p
Day's High
--
Day's Low
--
Volume
3,686,951
Avg. Vol
1,775,027
52-wk High
4.72p
52-wk Low
1.77p

OXB.L

Chart for OXB.L

About

Oxford BioMedica plc (Oxford BioMedica) is a biopharmaceutical company developing gene-based medicines and therapeutic vaccines. The Company is evaluating product candidates for four ocular indications, including uveitis and three undisclosed genetic retinal diseases. The Company's technology platform includes a LentiVector gene... (more)

Overall

Beta: -0.14
Market Cap (Mil.): £103.26
Shares Outstanding (Mil.): 2,565.39
Dividend: --
Yield (%): --

Financials

  OXB.L Industry Sector
P/E (TTM): -- 170.75 33.67
EPS (TTM): -0.01 -- --
ROI: -49.75 -1.87 17.39
ROE: -52.40 -7.13 18.21
Search Stocks

BRIEF-Oxford Biomedica buys Windrush Court Office for 3.2 mln stg

* Oxford Biomedica has acquired freehold of Windrush Court Office and laboratory facilities in transport way, Oxford, England, for a total cash consideration of £3.2 million Source text for Eikon: Further company coverage:

13 Oct 2014

BUZZ-Oxford Biomedica: Signs 3-year deal with Novartis

** Oxford Biomedica's shares rise more than 20 pct after the gene-and-cell-based therapeutics maker says it has signed a three-year contract with Novartis AG that could bring in up to $90 million for the British company.

10 Oct 2014

BRIEF-Oxford Biomedica signs further contract with Novartis for LentiVector

* Oxford Biomedica announces new process development and manufacturing collaboration which includes lentivector  licence agreement

10 Oct 2014

BRIEF-Oxford Biomedica H1 rev 4.7 mln pounds

* H1 net loss of £4.8 million (H1 2013 £5.9 million) Source text for Eikon: Further company coverage:

28 Aug 2014

BRIEF-Oxford Biomedica appoints Paul Blake chief development officer

* Paul Blake to take executive role as chief development officer Source text for Eikon: Further company coverage:

15 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Edison Investment Research
$10.00
Provider: MarketLine (a Datamonitor Company)
$50.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks